2006 proposed fee schedule - American Society of Clinical Oncology

seek comment on the potential impact on beneficiaries and
providers of possible changes to the inhalation drug
dispensing fee in 2006, as well as the impact of the new
drug benefit on inhalation drug access.
5. Supplying Fee
263
[If you choose to comment on issues in this section, please
include the caption “Supplying Fee” at the beginning of your
comments.]
Section 303(e)(2) of the MMA added section 1842(o)(6)
of the Act that requires the Secretary to pay a supplying
fee (less applicable deductible and coinsurance) to
pharmacies for certain Medicare Part B drugs and
biologicals, as determined appropriate by the Secretary.
The types of Medicare Part B drugs and biologicals eligible
for a supplying fee are immunosuppressive drugs described in
section 1861(s)(2)(J) of the Act, oral anticancer
chemotherapeutic drugs described in section 1861(s)(2)(Q) of
the Act, and oral anti-emetic drugs used as part of an
anticancer chemotherapeutic regimen described in section
1861(s)(2)(T) of the Act.
Beginning with CY 2005, we established a supplying fee
of $24 per prescription for these categories of drugs, with
a higher fee of $50 for the initial oral immunosuppressive
prescription supplied in the first month after a transplant.
When multiple drugs are supplied to a beneficiary, a